enGene Holdings Cash Flow Statement

Financials in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Year Ending	TTM	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021	Oct 31, 2020
Net Income	-112.91	-104.74	-29.02	-22.25	-16.65
Depreciation & Amortization	-	0.18	0.23	0.25	0.25
Share-Based Compensation	-	3.45	0.12	0.44	0.15
Other Operating Activities	112.91	71.55	6.52	6.77	1.61
Operating Cash Flow	-	-24.74	-17.59	-15.98	-13.06
Capital Expenditures	-	-0.32	-0.15	-0.25	-0.19
Investing Cash Flow	-	-0.32	-0.15	-0.25	-0.19
Share Issuance / Repurchase	-	64.3	0.01	0.01	0
Debt Issued / Paid	-	32.35	27.96	7.03	12.85
Other Financing Activities	-	-10.5	-	15.48	-
Financing Cash Flow	-	86.15	27.97	22.53	12.85
Exchange Rate Effect	-	0	-0.81	0.1	-0.05
Net Cash Flow	-	61.09	9.42	6.39	-0.46
Free Cash Flow	-	-25.06	-17.75	-16.23	-13.25
Free Cash Flow Per Share	-	-36.18	-27.09	-4.56	-4.80

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).